SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study

Table 2 Multivariable MR estimates of the effect of circulating metabolites on atrial fibrillation after adjusting for SGLT2 inhibition

Circulating metabolites	Method	OR (95% CI)	P	Q statistic	P-heterogeneity	Egger intercept	P-intercept
Compounds
Total concentration of lipoprotein particles	MV-IVW	0.88 (0.81, 0.96)	0.004	62.175	0.676
	MVMR-Egger	0.89 (0.82, 0.98)	0.012	62.283	0.673	0	0.928
Lipoprotein particles
Concentration of HDL particles	MV-IVW	0.89 (0.82, 0.97)	0.005	67.790	0.738
	MVMR-Egger	1.20 (0.83, 1.73)	0.468	66.669	0.769	-0.004	0.250

Odds ratio (OR), 95% confidence interval (CI), and P values were calculated for the respective method of MR analysis. The heterogeneity test in the IVW methods was performed using Cochran’s Q statistic. P < 0.025 was considered significant
HDL, high-density lipoprotein. MV-IVW, multivariable inverse–variance weighted; MVMR-Egger, multivariable MR-Egger; P-heterogeneity, P value for heterogeneity test; P-intercept, P value for the intercept of MR-Egger regression

ISSN: 1475-2840